Breast most cancers,World Well being Group https://www.who.int/news-room/fact-sheets/element/breast-cancer (2021).
Sung, H. et al. World most cancers statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 international locations. CA Most cancers J. Clin. 71, 209–249. https://doi.org/10.3322/caac.21660 (2021).
Pathology Primarily based Most cancers Frequency Knowledge – Sri Lanka: 2017. (Nationwide most cancers management programme, Sri Lanka, 2020).
Lanka, S. Supply: Globocan 2020 (World Well being Group, 2021).
Jackisch, C., Lammers, P. & Jacobs, I. Evolving panorama of human epidermal development issue receptor 2-positive breast most cancers therapy and the way forward for biosimilars. Breast 32, 199–216. https://doi.org/10.1016/j.breast.2017.01.010 (2017).
Wathuge, G. V. S. & Ratnatunga, N. V. I. Pathological traits of triple unfavourable breast most cancers phenotype in a cohort of Sri Lankan. J. Diagn. Pathol. 10, 21–31. https://doi.org/10.4038/jdp.v10i2.7678 (2016).
Balawardena, J., Skandarajah, T., Rathnayake, W. & Joseph, N. Breast most cancers survival in Sri Lanka. JCO Glob. Oncol. https://doi.org/10.1200/JGO.20.00003 (2020).
Gianni, L. et al. 5-year evaluation of neoadjuvant pertuzumab and trastuzumab in sufferers with regionally superior, inflammatory, or early-stage HER2-positive breast most cancers (NeoSphere): A multicentre, open-label, part 2 randomised trial. Lancet Oncol. 17, 791–800. https://doi.org/10.1016/s1470-2045(16)00163-7 (2016).
Nakashoji, A. et al. The up to date community meta-analysis of neoadjuvant remedy for HER2-positive breast most cancers. Most cancers Deal with. Rev. 62, 9–17. https://doi.org/10.1016/j.ctrv.2017.10.009 (2018).
Jiang, N. et al. Novel therapy methods for sufferers with HER2-positive breast most cancers who don’t profit from present focused remedy medicine. Exp. Ther. Med. 16, 2183–2192. https://doi.org/10.3892/etm.2018.6459 (2018).
Huober, J. et al. Survival outcomes of the NeoALTTO examine (BIG 1–06): up to date outcomes of a randomised multicenter part III neoadjuvant medical trial in sufferers with HER2-positive main breast most cancers. Eur. J. Most cancers 118, 169–177. https://doi.org/10.1016/j.ejca.2019.04.038 (2019).
Wang, J. & Xu, B. Focused therapeutic choices and future views for HER2-positive breast most cancers. Sign Transduct. Targ. Ther. 4, 34. https://doi.org/10.1038/s41392-019-0069-2 (2019).
Gianni, L. et al. Efficacy and security of neoadjuvant pertuzumab and trastuzumab in ladies with regionally superior, inflammatory, or early HER2-positive breast most cancers (NeoSphere): A randomised multicentre, open-label, part 2 trial. Lancet Oncol. 13, 25–32. https://doi.org/10.1016/S1470-2045(11)70336-9 (2012).
Gianni, L. et al. Neoadjuvant chemotherapy with trastuzumab adopted by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in sufferers with HER2-positive regionally superior breast most cancers (the NOAH trial): A randomised managed superiority trial with a parallel HER2-negative cohort. Lancet 375, 377–384. https://doi.org/10.1016/S0140-6736(09)61964-4 (2010).
Nitz, U. A. et al. De-escalation methods in HER2-positive early breast most cancers (EBC): Last evaluation of the WSG-ADAPT HER2+/HR- part II trial: efficacy, security, and predictive markers for 12 weeks of neoadjuvant twin blockade with trastuzumab and pertuzumab ± weekly paclitaxel. Ann. Oncol. J. Eur. Soc. Med. Oncol. 28, 2768–2772. https://doi.org/10.1093/annonc/mdx494 (2017).
Baselga, J. et al. Lapatinib with trastuzumab for HER2-positive early breast most cancers (NeoALTTO): A randomised, open-label, multicentre, part 3 trial. Lancet 379, 633–640. https://doi.org/10.1016/S0140-6736(11)61847-3 (2012).
Hurvitz, S. A. et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in sufferers with HER2-positive breast most cancers (KRISTINE): A randomised, open-label, multicentre, part 3 trial. Lancet Oncol. 19, 115–126. https://doi.org/10.1016/S1470-2045(17)30716-7 (2018).
Patel, T. A. et al. A randomized, managed part II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast most cancers (TEAL examine). Breast Most cancers Res. 21, 100. https://doi.org/10.1186/s13058-019-1186-0 (2019).
Guarneri, V. et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or each in human epidermal development issue receptor 2-positive operable breast most cancers: Outcomes of the randomized part II CHER-LOB examine. J. Clin. Oncol. 30, 1989–1995. https://doi.org/10.1200/JCO.2011.39.0823 (2012).
Chen, S., Liang, Y., Feng, Z. & Wang, M. Efficacy and security of HER2 inhibitors together with or with out pertuzumab for HER2-positive breast most cancers: a scientific evaluation and meta-analysis. BMC Most cancers 19, 973. https://doi.org/10.1186/s12885-019-6132-0 (2019).
Gunasekara, A. D. M. et al. Neoadjuvant therapy with HER2-targeted therapies in HER2-positive breast most cancers: A scientific evaluation and community meta-analysis. Cancers https://doi.org/10.3390/cancers14030523 (2022).
Wu, D. et al. Comparative efficacy and tolerability of neoadjuvant immunotherapy regimens for sufferers with HER2-positive breast most cancers: A community meta-analysis. J. Oncol. 2019, 3406972. https://doi.org/10.1155/2019/3406972 (2019).
NCCN Pointers Invasive Breast Most cancers (Model 5.2020) Nationwide Complete Most cancers Community <https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf> (2020).
Cardoso, F. et al. Early breast most cancers: ESMO Scientific Observe Pointers for prognosis, therapy and follow-up. Ann. Oncol. 30(8), 1194–1220. https://doi.org/10.1093/annonc/mdz173 (2019).
Squires, H. et al. Pertuzumab for the neoadjuvant therapy of early-stage HER2-positive breast most cancers: An proof evaluation group perspective of a NICE single know-how appraisal. PharmacoEconomics 36, 29–38. https://doi.org/10.1007/s40273-017-0556-7 (2018).
Attard, C. L. et al. Value-effectiveness evaluation of neoadjuvant pertuzumab and trastuzumab remedy for regionally superior, inflammatory, or early HER2-positive breast most cancers in Canada. J. Med. Econ 18, 173–188. https://doi.org/10.3111/13696998.2014.979938 (2015).
Hassett, M. J., Li, H., Burstein, H. J. & Punglia, R. S. Neoadjuvant therapy methods for HER2-positive breast most cancers: Value-effectiveness and high quality of life outcomes. Breast Most cancers Res. Deal with. 181, 43–51. https://doi.org/10.1007/s10549-020-05587-5 (2020).
Kapedanovska Nestorovska, A. et al. PCN89: Value effectiveness evaluation of pertuzumab as first line neoadjuvant therapy possibility for sufferers HER2 + breast most cancers in Republic of Macedonia. Worth Well being 21, S29. https://doi.org/10.1016/j.jval.2018.09.171 (2018).
Li, H. C. et al. PCN48 cost-effectiveness evaluation of pertuzumab with trastuzumab and chemotherapy in comparison with trastuzumab and chemotherapy within the neoadjuvant therapy of HER2-positive EARLY or regionally superior breast most cancers: Replace outcomes after nationwide drug reimbursement LIST adjustment in China. Worth Well being Reg. Points 22, S14. https://doi.org/10.1016/j.vhri.2020.07.098 (2020).
Wijeratne, D. T. et al. Demographic, tumour, and therapy traits of feminine sufferers with breast most cancers in Sri Lanka; outcomes from a hospital-based most cancers registry. BMC Most cancers 21, 1175. https://doi.org/10.1186/s12885-021-08929-8 (2021).
Ranawaka, S. et al. Breast cancer-related monetary toxicity in Sri Lanka: Insights from a decrease middle-income nation with free common public healthcare. Oncol. 29, e259–e265. https://doi.org/10.1093/oncolo/oyad259 (2023).
Nationwide Pointers for the Administration of Early and Regionally Superior Breast Most cancers in Sri Lanka (Nationwide Most cancers Management Programme, Ministry of Well being, Sri Lanka, 2021).
Fernando, A., Jayarajah, U., Prabashani, S., Fernando, E. A. & Seneviratne, S. A. Incidence developments and patterns of breast most cancers in Sri Lanka: an evaluation of the nationwide most cancers database. BMC Most cancers 18, 482. https://doi.org/10.1186/s12885-018-4408-4 (2018).
Mylonas, C., Kourlaba, G., Skroumpelos, A. & Maniadakis, N. Financial analysis of pertuzumab neoadjuvant therapy for sufferers with regionally superior, inflammatory, or early stage HER2-positive breast most cancers in Greece. Worth Well being 19, A735. https://doi.org/10.1016/j.jval.2016.09.2222 (2016).
Ribeiro, I. et al. Financial analysis of pertuzumab together with trastuzumab and docetaxel within the neoadjuvant therapy of girls with HER2-positive, regionally superior, inflammatory or early breast most cancers in Portugal. Worth Well being 19, A736–A737. https://doi.org/10.1016/j.jval.2016.09.2231 (2016).
Pertuzumab for the neoadjuvant therapy of HER2-positive breast most cancers. Expertise appraisal steerage. Committee Papers (Nationwide Institute for Well being and Care Excellence, 2016).
World Well being, O. et al. (World Well being Group, Geneva, 2003).
De Azambuja, E. et al. Lapatinib with trastuzumab for HER2-positive early breast most cancers (NeoALTTO): Survival outcomes of a randomised, open-label, multicentre, part 3 trial and their affiliation with pathological full response. Lancet Oncol. 15, 1137–1146. https://doi.org/10.1016/S1470-2045(14)70320-1 (2014).
Swain, S. M. et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast most cancers (CLEOPATRA): Finish-of-study outcomes from a double-blind, randomised, placebo-controlled, part 3 examine. Lancet Oncol. 21, 519–530. https://doi.org/10.1016/s1470-2045(19)30863-0 (2020).
Hurvitz, S. A. et al. Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal development issue receptor 2–optimistic breast most cancers: Three-year outcomes from the part III KristinE examine. J. Clin. Oncol. 37, 2206–2216. https://doi.org/10.1200/JCO.19.00882 (2019).
Wang, X. et al. Outcomes following salvage radiation and systemic remedy for remoted locoregional recurrence of breast most cancers after mastectomy: Affect of constructed biologic subtype. J. Oncol. 2018, 4736263. https://doi.org/10.1155/2018/4736263 (2018).
Hamilton, S. N., Tyldesley, S., Li, D., Olson, R. & McBride, M. Second malignancies after adjuvant radiation remedy for early stage breast most cancers: is there elevated threat with addition of regional radiation to native radiation?. Int. J. Radiat. Oncol. Biol. Phys. 91, 977–985. https://doi.org/10.1016/j.ijrobp.2014.12.051 (2015).
Life Tables for Sri Lanka 2011–2013 By District and Intercourse. (Division of Census and Statistics, Ministry of Nationwide Insurance policies and Financial Affairs, Sri Lanka).
Verrill, M. et al. Well being-related high quality of life and work productiveness in UK sufferers with HER2-positive breast most cancers: a cross-sectional examine evaluating the relationships between illness and therapy stage. Well being Qual. Life Outcomes https://doi.org/10.1186/s12955-020-01603-w (2020).
Li, S., Wang, M., Liu, L. & Chen, G. Which strategy is best in eliciting well being state utilities from breast most cancers sufferers? Proof from mainland China. Eur J Most cancers Care 28, e12965. https://doi.org/10.1111/ecc.12965 (2019).
Malalasekara, A. P., Ariyaratne, M. H. J., Fernando, R., Perera, D. & Deen, Ok. I. Value accounting in a surgical unit in a instructing hospital-a pilot examine. Ceylon Med. J. 48, 71–74. https://doi.org/10.4038/cmj.v48i3.3342 (2011).
Monetary Particulars: Value Accounting. (Ministry of Well being, Sri Lanka, 2021).
Chulasiri, M. P. P. U. Prevalence and related components of smoking amongst grownup males in Colombo district and price of therapy of lung most cancers attributed to smoking, College of Colombo, (2014).
Financial and Social Statistics of Sri Lanka. (Statstics Division, Central Financial institution of Sri Lanka, Colombo, 2020).
Most cancers Incidence and mortality information Sri Lanka 2015. (Nationwide most cancers management programme, Sri Lanka, 2015).
Actions of CCPI (Division of Census and Statistics, Sri Lanka).
Actions of NCPI. (Deaprtment of Census and Statistics, Sri Lanka).
Shopping for and Promoting Alternate Charges. (Central Financial institution of Sri Lanka, 2022).
Jayawardena, R. & Hills, A. P. Physique composition derived Physique Mass Index and Waist Circumference cut-offs for Sri Lankan adults. Weight problems Drugs 18, 100214. https://doi.org/10.1016/j.obmed.2020.100214 (2020).
Riewpaiboon, A. Measurement of prices for well being financial analysis. J. Med. Assoc. Thailand 97(5), S17-26 (2014).
Palliative Care Guide for Well being Care Professionals in Sri Lanka. 2 edn, (Palliative Care and Finish of Life Care Taskforce, Sri Lanka Medical Affiliation, 2021).
Sandamali, J. A. N. et al. Anthracycline-induced cardiotoxicity in breast most cancers sufferers from southern Sri Lanka: An echocardiographic evaluation. Biomed Res. Int. 2020, 1847159. https://doi.org/10.1155/2020/1847159 (2020).
Annual Report of the Financial Board to the Hon. Minister of Finance for the 12 months 2021. (Central Financial institution of Sri Lanka, Colombo, 2022).
Hutubessy, R., Chisholm, D. & Edejer, T.T.-T. Generalized cost-effectiveness evaluation for national-level priority-setting within the well being sector. Value Eff. Resour. Alloc. 1, 8–8. https://doi.org/10.1186/1478-7547-1-8 (2003).
Marseille, E., Larson, B., Kazi, D. S., Kahn, J. G. & Rosen, S. Thresholds for the cost-effectiveness of interventions: Different approaches. Bull. World Well being Organ. 93, 118–124. https://doi.org/10.2471/BLT.14.138206 (2015).
Guarneri, V. et al. Survival after neoadjuvant remedy with trastuzumab-lapatinib and chemotherapy in sufferers with HER2-positive early breast most cancers: A meta-analysis of randomized trials. ESMO Open 7, 100433. https://doi.org/10.1016/j.esmoop.2022.100433 (2022).
Kunst, N. et al. Value-effectiveness of neoadjuvant-adjuvant therapy methods for ladies With ERBB2 (HER2)-positive breast most cancers. JAMA Community Open 3, e2027074. https://doi.org/10.1001/jamanetworkopen.2020.27074 (2020).
Wenzl, M. & Chapman, S. Efficiency-based managed entry agreements for brand spanking new medicines in OECD international locations and EU member states.https://doi.org/10.1787/6e5e4c0f-en
Bognar, C. L. F. B., Bychkovsky, B. L. & Lopes, G. D. L. Obligatory licenses for most cancers medicine: Does circumventing patent rights enhance entry to oncology drugs?. J. Glob. Oncol. 2, 292–301. https://doi.org/10.1200/JGO.2016.005363 (2016).
Sensible, J. Licensing deal for most cancers drug will improve entry in low and center earnings international locations. BMJ 379, o2532. https://doi.org/10.1136/bmj.o2532 (2022).
Inflation in December 2022. (Central Financial institution of Sri Lanka, 2022).
Inflation and prices-Month-to-month NCPI. (Division of Census and Statistics, Sri Lanka, 2023).
